Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics Development
Basal Cell Carcinoma (Basal Cell Epithelioma) - Drug Profiles
Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects
Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products
Basal Cell Carcinoma (Basal Cell Epithelioma) - Product Development Milestones
Featured News & Press Releases
Jul 12, 2022: Turn Therapeutics announces positive in-vivo data for non-melanoma skin cancer candidate
Jul 11, 2022: MediWound announces positive initial data from its U.S. Phase I/II Study of MW005 for the treatment of basal cell carcinoma
Apr 05, 2022: Lytix Biopharma receives milestone payment from Verrica Pharmaceuticals triggered by first patient dosed with LTX-315
Apr 05, 2022: Verrica Pharmaceuticals announces first patient dosed in phase 2 study of LTX-315, a potential first-in-class oncolytic peptide-based immunotherapy, for the treatment of basal cell carcinoma
Mar 28, 2022: At the 2022 AAD Annual Meeting, Senhwa presents positive initial data from clinical trial of Silmitasertib used to treat patients with advanced basal cell carcinoma
Feb 23, 2022: Siromics announces interim data from phase II clinical trial of STP705 for treatment of Cutaneous Basal Cell Carcinoma
Feb 01, 2022: Biofrontera provides update on patient recruitment for phase III study for the treatment of sBCC with Ameluz-PDT
Dec 16, 2021: Senhwa clinical data abstract for silmitasertib in patients with advanced basal cell carcinoma accepted for 2022 AAD Annual Meeting
Nov 18, 2021: Verrica Pharmaceuticals announces FDA acceptance of its IND application for LTX-315, a potential first-in-class oncolytic peptide-based immunotherapy, for the treatment of basal cell carcinoma
Oct 29, 2021: Libtayo (cemiplimab) approved in Cada for locally advanced basal cell carcinoma (BCC) patients
Aug 12, 2021: Positive data from the remetinostat phase II study in basal cell carcinoma published in Clinical Cancer Research
Aug 06, 2021: Medivir: First-in-class histone deacetylase inhibitor gel shows promise for the treatment of patients with basal cell carcinoma
Jul 26, 2021: MediWound announces initiation of U.S. phase I/II study of MW005 for the treatment of basal cell carcinoma
Jun 25, 2021: Sanofi: Libtayo (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
Jun 07, 2021: MediWound announces peer-reviewed paper of a case series report of basal cell carcinoma published in the Open Dermatology Jourl
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, 2022
Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products, 2022